Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells

Prostate

Volumn 48, Issue 4, 2001, Pages 254-264

  Lanzi, Cinzia ^a   Cassinelli, Giuliana ^a   Cuccuru, Giuditta ^a   Supino, Rosanna ^a   Zuco, Valentina ^a   Ferlini, Cristiano ^b   Scambia, Giovanni ^c   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Laboratory Immunologia   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cell cycle checkpoints; Cell death; Paclitaxel; Prostatic neoplasms; Protein p21WAF1; Protein p53

Indexed keywords

PACLITAXEL; PROTEIN P21; TAXANE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CDC2 PROTEIN KINASE; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; MALE; MICROTUBULES; PACLITAXEL; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED;

EID: 0035450447     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1105     Document Type: Article

References (52)

1. Paclitaxel pharmacology and other tumor types
2. Docetaxel (Taxotere) in hormone-refractory prostate cancer
3. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
4. Taxol induces bc-2 phosphorylation and death of prostate cancer cells
5. Mechanisms of action of taxanes in prostate cancer
6. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
7. Cell cycle checkpoints: Preventing an identity crisis
8. Cell cycle control and cancer chemotherapy
9. Predicting response to cancer chemotherapy: The role of p53
10. Chromosome segregation: Dual control ensures fidelity
11. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption
12. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations
13. Mechanisms of taxol-induced cell death are concentration dependent
14. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis
15. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol-induced growth arrest
16. cdc2 coincident with paclitaxel-induced apoptosis
17. Up-regulation of CDC2 protein during paclitaxel-induced apoptosis
18. Loss of normal p53 function confers sensitization to paclitaxel by increasing G2/M arrest and apoptosis
19. Taxol, vincristine or nocodazole induces lethality in G-checkpoint-defective human astrocytoma U373MG cells by triggering hyperploid progression
20. Differential taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells
21. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis
22. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes
23. 1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitorinduced apoptosis
24. 1 arrest
25. Monoclonal antobodies to mitotic cells
26. Analysis of apoptosis by laser scanning cytometry
27. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas
28. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
29. WAF1 expression induces differentiation-specific cell cycle changes in PC12 cells characteristic of nerve growth factor treatment
30. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
31. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis
32. Mitosis in transition
33. Mitotic Raf-1 is stimulated independently of Ras and is active in the cytoplasm
34. L is phosphorylated in malignant cells following microtubule disruption
35. Extended survivability of prostate cancer cells in the absence of trophic factors: Increased proliferation, evasion of apoptosis, and the role of apoptosis proteins
36. Probing chromatin structure in the early phases of apoptosis
37. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line
38. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: Inhibition of cell cycle progression and induction of cell death
39. The retinoblastoma protein and cell cycle control
40. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation
41. Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity
42. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53alleles
43. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines
44. Inhibition of DNA replication factor RPA by p53
45. Cell death beyond apoptosis
46. p21-containing cyclin kinases exist in both active and inactive states
47. Waf1/Cip1 modulates proliferating cell nuclear antigen binding
48. Cip1 at the onset of mitosis: A role at the G2/M-phase transition
49. Molecular effects of paclitaxel: Myths and reality (a critical review)
50. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma
51. Mutations of the p16 gene product are rare in prostate cancer
52. Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers